These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33466775)

  • 1. Biologically Active Tissue Factor-Bearing Larger Ectosome-Like Extracellular Vesicles in Malignant Effusions from Ovarian Cancer Patients: Correlation with Incidence of Thrombosis.
    Steidel C; Ender F; Rody A; von Bubnoff N; Gieseler F
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33466775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-level secretion of tissue factor-rich extracellular vesicles from ovarian cancer cells mediated by filamin-A and protease-activated receptors.
    Koizume S; Ito S; Yoshioka Y; Kanayama T; Nakamura Y; Yoshihara M; Yamada R; Ochiya T; Ruf W; Miyagi E; Hirahara F; Miyagi Y
    Thromb Haemost; 2016 Jan; 115(2):299-310. PubMed ID: 26446354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers.
    Yamamoto CM; Oakes ML; Murakami T; Muto MG; Berkowitz RS; Ng SW
    J Ovarian Res; 2018 Mar; 11(1):20. PubMed ID: 29499737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular vesicles derived from ascitic fluid enhance growth and migration of ovarian cancer cells.
    Mitra A; Yoshida-Court K; Solley TN; Mikkelson M; Yeung CLA; Nick A; Lu K; Klopp AH
    Sci Rep; 2021 Apr; 11(1):9149. PubMed ID: 33911091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms.
    Gomes FG; Sandim V; Almeida VH; Rondon AMR; Succar BB; Hottz ED; Leal AC; Verçoza BRF; Rodrigues JCF; Bozza PT; Zingali RB; Monteiro RQ
    Thromb Res; 2017 Nov; 159():24-32. PubMed ID: 28950217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small extracellular vesicles from malignant ascites of patients with advanced ovarian cancer provide insights into the dynamics of the extracellular matrix.
    Bortot B; Apollonio M; Rampazzo E; Valle F; Brucale M; Ridolfi A; Ura B; Addobbati R; Di Lorenzo G; Romano F; Buonomo F; Ripepi C; Ricci G; Biffi S
    Mol Oncol; 2021 Dec; 15(12):3596-3614. PubMed ID: 34614287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular vesicles from malignant effusions induce tumor cell migration: inhibitory effect of LMWH tinzaparin.
    Gamperl H; Plattfaut C; Freund A; Quecke T; Theophil F; Gieseler F
    Cell Biol Int; 2016 Oct; 40(10):1050-61. PubMed ID: 27435911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher EpCAM-Positive Extracellular Vesicle Concentration in Ascites Is Associated with Shorter Progression-Free Survival of Patients with Advanced High-Grade Serous Carcinoma.
    Herzog M; Verdenik I; Kobal B; Černe K
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic analysis of ascitic extracellular vesicles describes tumour microenvironment and predicts patient survival in ovarian cancer.
    Vyhlídalová Kotrbová A; Gömöryová K; Mikulová A; Plešingerová H; Sladeček S; Kravec M; Hrachovinová Š; Potěšil D; Dunsmore G; Blériot C; Bied M; Kotouček J; Bednaříková M; Hausnerová J; Minář L; Crha I; Felsinger M; Zdráhal Z; Ginhoux F; Weinberger V; Bryja V; Pospíchalová V
    J Extracell Vesicles; 2024 Mar; 13(3):e12420. PubMed ID: 38490958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer.
    Yokoi A; Yoshioka Y; Yamamoto Y; Ishikawa M; Ikeda SI; Kato T; Kiyono T; Takeshita F; Kajiyama H; Kikkawa F; Ochiya T
    Nat Commun; 2017 Mar; 8():14470. PubMed ID: 28262727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Aspects of Extracellular Vesicles as Mediators of Cancer-Associated Thrombosis.
    Almeida VH; Rondon AMR; Gomes T; Monteiro RQ
    Cells; 2019 Jul; 8(7):. PubMed ID: 31337034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue factor activity on microvesicles from cancer patients.
    Ender F; Freund A; Quecke T; Steidel C; Zamzow P; von Bubnoff N; Gieseler F
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):467-475. PubMed ID: 31734835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells.
    Yokota N; Koizume S; Miyagi E; Hirahara F; Nakamura Y; Kikuchi K; Ruf W; Sakuma Y; Tsuchiya E; Miyagi Y
    Br J Cancer; 2009 Dec; 101(12):2023-9. PubMed ID: 19904262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
    Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
    Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy.
    Zwicker JI; Liebman HA; Neuberg D; Lacroix R; Bauer KA; Furie BC; Furie B
    Clin Cancer Res; 2009 Nov; 15(22):6830-40. PubMed ID: 19861441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study.
    van Es N; Hisada Y; Di Nisio M; Cesarman G; Kleinjan A; Mahé I; Otten HM; Kamphuisen PW; Berckmans RJ; Büller HR; Mackman N; Nieuwland R
    Thromb Res; 2018 Jun; 166():54-59. PubMed ID: 29656167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells.
    Boddu VK; Zamzow P; Kramer MW; Merseburger AS; Gorantla SP; Klinger M; Cramer L; Sauer T; Gemoll T; von Bubnoff N; Gieseler F; Darabi M
    Cell Commun Signal; 2024 Feb; 22(1):129. PubMed ID: 38360687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EV-Associated MMP9 in High-Grade Serous Ovarian Cancer Is Preferentially Localized to Annexin V-Binding EVs.
    Reiner AT; Tan S; Agreiter C; Auer K; Bachmayr-Heyda A; Aust S; Pecha N; Mandorfer M; Pils D; Brisson AR; Zeillinger R; Lim SK
    Dis Markers; 2017; 2017():9653194. PubMed ID: 28607529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential biomarker profiles between unprovoked venous thromboembolism and cancer.
    Sánchez-López V; Gao L; Ferrer-Galván M; Arellano-Orden E; Elías-Hernández T; Jara-Palomares L; Asensio-Cruz MI; Castro-Pérez MJ; Rodríguez-Martorell FJ; Lobo-Beristain JL; Ballaz-Quincoces A; López-Campos JL; Vila-Liante V; Otero-Candelera R
    Ann Med; 2020 Sep; 52(6):310-320. PubMed ID: 32634035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.
    Lane D; Robert V; Grondin R; Rancourt C; Piché A
    Int J Cancer; 2007 Sep; 121(6):1227-37. PubMed ID: 17534891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.